Michael J. Strong, MD, FRCP(C), FANN, FCAHS
Professor of Neurology and Dean of the Schulich School of Medicine and Dentistry, Western University
Office: London Health Sciences Centre, University Hospital C7-120, CSB 3700
Secretary: Sherry Conrad
Dr. Michael J. Strong is Dean of the Schulich School of Medicine & Dentistry and Distinguished University Professor at Western University. He also holds the Arthur J. Hudson Chair in ALS Research. He undertook his undergraduate training in biochemistry and medicine at Queens University in Kingston (1976 – 1982), neurology training at Western University (1982 – 1987), and postgraduate training at the Laboratory of Central Nervous System Studies (director - D. Carleton Gadjusek, Nobel Laureate) at the National Institutes of Health, Bethesda, Maryland under the supervision of Ralph M. Garruto, PhD (1987 - 1990).
Dr. Strong joined the Department in 1990 and is currently a scientist at the Robarts Research Institute, and served from 2000 to 2010 as the Chief of Neurology and Co-chair of the Department of Clinical Neurological Sciences at the London Health Sciences Centre and Western University. He has also served as Co-chair of the Canadian ALS Research Consortium and is a former member of the Board of Directors of the ALS Society of Canada. Dr. Strong is the lead investigator for the Ontario Neurodegenerative Research Institute (ONDRI), which received $28.5M in sponsorship funding from the Ontario Brain Institute.
Dr. Strong is the editor of the text “Amyotrophic Lateral Sclerosis and the Frontotemporal Dementias” (Oxford University Press, 2010), “Dementia and Motor Neuron Disease” (Taylor & Francis Press) co-editor with Professor Pamela Shaw of the text “Amyotrophic Lateral Sclerosis” (Blue Book Series). He has published over 175 peer-reviewed articles and 29 chapters and given over 155 invited lectures nationally and internationally related to his research in ALS.
Dr. Strong was awarded the Sheila Essay Award in 2005 and the Forbes Norris Award in 2008, and is the only Canadian to have received both international awards for ALS research. He was elected as a fellow of the American Academy of Neurology in 2008. In 2009, he was elected a Fellow of the Canadian Academy of Health Sciences and in 2012, he received the Queen Elizabeth II Diamond Jubilee Medal for his work in ALS.
Dr. Strong's research has focused on understanding the cellular biology of ALS (Lou Gehrig’s disease) and has led to an understanding of the mechanisms by which intracellular deposits of protein (composed primarily of neurofilament) are formed, and how these aggregates contribute to the disease process of ALS. His research has also contributed to the understanding of neuropsychological deficits in ALS, both clinically and at the cellular level.
Lou Gehrig's Disease (ALS: degeneration of motor neurons), Motor Neuron Diseases, Neurotoxicity
Honours and Awards
- 2012, Queen Elizabeth II Diamond Jubilee Medal
- 2012, Excellence in teaching Award, Western University Students' Council
- 2012, Teaching Honour Roll Certificate, Western University
- 2009, Distinguished University Professorhsip Award, Western University
- 2008, Excellence in Teaching Award, Western University
- 2007, Excellence in Teaching Award, Western University
- 2006, Faculty scholar, Schulich School of Medicine & Dentistry
- 2006, Excellence in Teaching Award, Western University
- 2005, Excellence in Teaching Award, Western University
- 2004, Excellence in Teaching Award, Western University
Hawley ZCE, Campos-Melo D, Strong MJ. Novel miR-b2122 regulates several ALS-related RNA-binding proteins. Mol Brain. 2017 Oct 2;10(1):46. doi: 10.1186/s13041-017-0326-7. PubMed PMID: 28969660.
Farhan SMK, Gendron TF, Petrucelli L, Hegele RA, Strong MJ. ARHGEF28 p.Lys280Metfs40Ter in an amyotrophic lateral sclerosis family with a C9orf72 expansion. Neurol Genet. 2017 Sep 22;3(5):e190. doi: 10.1212/NXG.0000000000000190. eCollection 2017 Oct. PubMed PMID: 28971145; PubMed Central PMCID: PMC5616022.
Strong MJ. Revisiting the concept of amyotrophic lateral sclerosis as a multisystems disorder of limited phenotypic expression. Curr Opin Neurol. 2017 Sep 13. doi: 10.1097/WCO.0000000000000488. [Epub ahead of print] PubMed PMID: 28914734.
Strong MJ, Busing N, Goosney DL, Harris KA, Horsley T, Kuzyk A, Lingard L, Norman WV, Rosenblum ND, Saryeddine T, Wang X. The Rising Challenge of Training Physician-Scientists: Recommendations From a Canadian National Consensus Conference. Acad Med. 2017 Aug 16. doi: 10.1097/ACM.0000000000001857. [Epub ahead of print] PubMed PMID: 28817429.
Cheung K, Droppelmann CA, MacLellan A, Cameron I, Withers B, Campos-Melo D, Volkening K, Strong MJ. Rho guanine nucleotide exchange factor (RGNEF) is a prosurvival factor under stress conditions. Mol Cell Neurosci. 2017 Jul;82:88-95. doi: 10.1016/j.mcn.2017.05.003. Epub 2017 May 8. PMID: 28495450
Montero-Odasso M, Pieruccini-Faria F, Bartha R, Black SE,Finger E, Freedman M, Greenberg B, Grimes DA, Hegele RA, Hudson C, Kleinstiver PW, Lang AE, Masellis M, McLaughlin PM, Munoz DP, Strother S, Swartz RH, Symons S, Tartaglia MC, Zinman L,Strong MJ; Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). ONDRI Investigators., McIlroy W.J Alzheimers Dis. 2017 Jun 27. doi: 10.3233/JAD-170149. [Epub ahead of print] PubMed PMID: 28671116.
Volkening K, Strong WL, Seaton S, Yang W, Strong MJ. C9orf72 mutations do not influence the tau signature of amyotrophic lateral sclerosis with cognitive impairment (ALSci). Amyotroph Lateral Scler Frontotemporal Degener. 2017 May 31:1-6. doi: 10.1080/21678421.2017.1332075. [Epub ahead of print] PMID: 28562075
Hawley ZCE, Campos-Melo D, Droppelmann CA, Strong MJ. MotomiRs: miRNAs in Motor Neuron Function and Disease.Front Mol Neurosci. 2017 May 4;10:127. doi: 10.3389/fnmol.2017.00127. eCollection 2017. Review. PMID: 28522960
Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, HortobáGyi T, Rosenfeld J, Silani V, Ince PG, Turner MR. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):153-174. doi: 10.1080/21678421.2016.1267768. Epub 2017 Jan 5. PMID: 28054827
Farhan SM, Bartha R, Black SE, Corbett D, Finger E, Freedman M, Greenberg B, Grimes DA, Hegele RA, Hudson C, Kleinstiver PW, Lang AE, Masellis M, McIlroy WE, McLaughlin PM, Montero-Odasso M, Munoz DG, Munoz DP, Strother S, Swartz RH, Symons S, Tartaglia MC, Zinman L; ONDRI Investigators, Strong MJ. The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Can J Neurol Sci. 2017 Mar;44(2):196-202. doi: 10.1017/cjn.2016.415. Epub 2016 Dec 22. PMID:28003035
Moszczynski AJ, Yang W, Hammond R, Ang LC, Strong MJ. Threonine175, a novel pathological phosphorylation site on tau protein linked to multiple tauopathies. Acta Neuropathol Commun. 2017 Jan 11;5(1):6. doi: 10.1186/s40478-016-0406-4. PMID: 28077166
- Researchers close in on drugs for severe head injury, ALS - CBC London
- London Medical Network announces $6.8 million 3D printing partnership with Western U and Renishaw PLC - Global News
- Freeze on ALS research progress continues - The Varsity
- Rowan's Law: Committee will examine dangers of youth concussions - CBC News
- Our ticket? Health care - London Free Press
- Robarts Clinical Trials moving downtown - The Londoner
- Western University reversing the brain drain in London - London Free Press
- Concussion research and education gets stronger at Western - The Londoner